5890 related articles for article (PubMed ID: 3530176)
1. [Combination chemotherapy of disseminated skin melanoma with nitrosomethylurea].
Perevodchikova NJ; Moros LW; Kogonia LM
Arch Geschwulstforsch; 1986; 56(4):273-81. PubMed ID: 3530176
[TBL] [Abstract][Full Text] [Related]
2. [Comparison of the efficacy of imidazole-carboxamide and of a combination of nitrosomethylurea, vincristine and dactinomycin in disseminated melanoma].
Kogoniia LM; Moroz LV; Perevodchikova NI; Platinskiĭ LV; Borisov AI
Vopr Onkol; 1981; 27(4):16-21. PubMed ID: 7015692
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy of disseminated melanoma with bleomycin, vincristine, CCNU, and DTIC (BOLD regimen). The Prudente Foundation Melanoma Study Group.
Cancer; 1989 May; 63(9):1676-80. PubMed ID: 2467736
[TBL] [Abstract][Full Text] [Related]
4. Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF.
Bottoni U; Bonaccorsi P; Devirgiliis V; Panasiti V; Borroni RG; Trasimeni G; Clerico R; Calvieri S
Jpn J Clin Oncol; 2005 Sep; 35(9):507-13. PubMed ID: 16120623
[TBL] [Abstract][Full Text] [Related]
5. Modern problems of clinical chemotherapy of malignant tumours.
Perevodchikova NI; Bychkov MB
Arch Geschwulstforsch; 1980; 50(7):657-63. PubMed ID: 6263209
[TBL] [Abstract][Full Text] [Related]
6. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
Rudolf Z; Strojan P
Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
[TBL] [Abstract][Full Text] [Related]
7. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy.
Legha SS
Semin Oncol; 1997 Feb; 24(1 Suppl 4):S39-43. PubMed ID: 9122733
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of repeat isolated limb infusion with melphalan and actinomycin D for recurrent melanoma.
Kroon HM; Lin DY; Kam PC; Thompson JF
Cancer; 2009 May; 115(9):1932-40. PubMed ID: 19288571
[TBL] [Abstract][Full Text] [Related]
9. [Chemotherapy of malignant melanoma--current status].
Karg C; Garbe C; Orfanos CE
Hautarzt; 1990 Feb; 41(2):56-65. PubMed ID: 2180855
[TBL] [Abstract][Full Text] [Related]
10. Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up.
Carmo-Pereira J; Costa FO; Henriques E
Cancer Treat Rep; 1984 Oct; 68(10):1211-4. PubMed ID: 6525593
[TBL] [Abstract][Full Text] [Related]
11. [New combination chemotherapy for malignant melanoma--PAV(peplomycin, ACNU, VCR) therapy].
Ikeda S; Tajima K; Miyasato H; Terakado T; Suzuki T; Miura T
Gan To Kagaku Ryoho; 1983 Oct; 10(10):2198-204. PubMed ID: 6194756
[TBL] [Abstract][Full Text] [Related]
12. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
13. [Chemotherapy in disseminated malignant skin melanoma with a combination of nitrosomethylurea, vincristine, peplomycin or bleomycetin].
Tanaev VG; Gershanovich MA
Vopr Onkol; 1991; 37(2):162-7. PubMed ID: 1707570
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of second-line therapy with DTIC, BCNU, cisplatin and tamoxifen (Dartmouth regimen) chemotherapy in patients with malignant melanoma previously treated with dacarbazine.
Propper DJ; Braybrooke JP; Levitt NC; O'Byrne K; Christodoulos K; Han C; Talbot DC; Ganesan TS; Harris AL
Br J Cancer; 2000 Jun; 82(11):1759-63. PubMed ID: 10839287
[TBL] [Abstract][Full Text] [Related]
15. [Chemoimmunotherapy with dacarbazine and aranose combined with interferon-alpha in disseminated cutaneous melanoma].
Gershanovich ML; Akimov MA
Vopr Onkol; 2004; 50(2):179-83. PubMed ID: 15176220
[TBL] [Abstract][Full Text] [Related]
16. DTIC and combination therapy for melanoma. II. Escalating schedules of DTIC with BCNU, CCNU, and vincristine.
Hill GJ; Metter GE; Krementz ET; Fletcher WS; Golomb FM; Ramirez G; Grage TB; Moss SE
Cancer Treat Rep; 1979; 63(11-12):1989-92. PubMed ID: 393384
[No Abstract] [Full Text] [Related]
17. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
18. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
19. Outcomes following isolated limb infusion for melanoma. A 14-year experience.
Kroon HM; Moncrieff M; Kam PC; Thompson JF
Ann Surg Oncol; 2008 Nov; 15(11):3003-13. PubMed ID: 18509706
[TBL] [Abstract][Full Text] [Related]
20. Randomized phase 2/3 trial of CpG oligodeoxynucleotide PF-3512676 alone or with dacarbazine for patients with unresectable stage III and IV melanoma.
Weber JS; Zarour H; Redman B; Trefzer U; O'Day S; van den Eertwegh AJ; Marshall E; Wagner S
Cancer; 2009 Sep; 115(17):3944-54. PubMed ID: 19536884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
